BridgeBio lands $1B from Sixth Street, KKR to fuel drug launches
What's the deal? BridgeBio has raised $1 billion in preferred equity to accelerate its current and upcoming drug launches.
The financing was led by Sixth StreetDealroom has a profile for this one. Try Dealroom →, with participation from HealthCare RoyaltyDealroom has a profile for this one. Try Dealroom →, a business of KKR.
The deal carries an initial conversion price of roughly $138 per share — a premium of more than 100% to the company's 30-day volume-weighted average price.
Why now? BridgeBio is moving to fund commercial launches, and the capital gives it firepower to push products to market without diluting shareholders at current prices.
The steep conversion premium signals confidence from its backers that the stock has room to climb.
What could go wrong? Preferred equity sits ahead of common shares, so existing holders take on added risk if launches stumble.
Conversion at $138 would only reward investors if the share price roughly doubles — a bet that hinges on commercial execution.
The signal: BridgeBio's late-stage status makes it a natural fit for structured capital from investment funds like Sixth Street and KKR, which increasingly favour non-dilutive instruments over traditional equity when backing genetic disease developers on the cusp of commercialisation.
Read more: Aktiencheck, Bloomberg
Image credit: National Institutes of Health (NIH)
